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IL-6 and Its Soluble Receptor Orchestrate
a Temporal Switch in the Pattern of Leukocyte
Recruitment Seen during Acute Inflammation
also influence leukocyte recruitment, since accumulation
of neutrophils at sites of infection or inflammation is sup-
pressed by its action (Ulich et al., 1991; Barton and Jackson,
1993; Xing et al., 1998). Indeed, exposure of IL-6-deficient
(IL-6/) mice to an endotoxin aerosol results in a signifi-
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Summary Peritoneal inflammation is a recurrent complication of
end-stage renal failure patients on continuous ambulatory
During acute inflammation, leukocyte recruitment is peritoneal dialysis (CAPD). This clinical condition provides
characterized by an initial infiltration of neutrophils, us with a unique opportunity to study the temporal impor-
which are later replaced by a more sustained popula- tance of cytokine networks in a human inflammatory situa-
tion of mononuclear cells. Based on both clinical and tion. A diagnostic feature of this condition is the rapid accu-
experimental evidence, we present a role for IL-6 and mulation of neutrophils within the peritoneal cavity over the
its soluble receptor (sIL-6R) in controlling this pattern first 12–24 hr of infection (Topley et al., 1996). However, a
more sustained population of monocytes and lymphocytesof leukocyte recruitment during peritoneal inflamma-
subsequently replaces this initial neutrophil influx (Bellingantion. Liberation of sIL-6R from the initial neutrophil
et al., 1996). Ultimately, it is this temporal switch in theinfiltrate acts as a regulator of CXC and CC chemokine
recruitment of leukocyte subpopulations that determinesexpression, which contributes to a suppression of
whether the infection is cleared (Bellingan et al., 1996; Di-neutrophil recruitment and the concurrent attraction
Tirro et al., 1998). To date, the biological mediators control-of mononuclear leukocytes. Soluble IL-6R-mediated
ling this critical step are largely undefined. Here, we providesignaling is therefore an important intermediary in the
evidence that sIL-6R is associated with the regulation ofresolution of inflammation and supports transition be-
this process, which suggests that sIL-6R contributes to thetween the early predominantly neutrophilic stage of
successful resolution of inflammation. Overall, the findingsan infection and the more sustained mononuclear cell
presented here may offer an explanation as to how the
influx.
previously described pro- and antiinflammatory properties
of IL-6 contribute to the progression of an inflammatory
Introduction event.
Interleukin-6 (IL-6) has been described as having both pro- Results
and antiinflammatory effects. In terms of its protective prop-
erties, IL-6 appears to moderate the extent of an inflamma- Soluble IL-6R Levels during Peritoneal Inflammation
tory response through its ability to block proinflammatory Peritoneal effluents were obtained from patients on CAPD,
cytokine expression and by promoting release of IL-1 recep- with overt clinical peritonitis. Samples were collected during
tor antagonist and the soluble p55 TNF receptor (Schindler the first 5 days of infection and from the same individuals
et al., 1990; Tilg et al., 1994; Xing et al., 1998). IL-6 may 3–6 months after resolution of the condition. Significantly
elevated levels of IL-6, IL-8, and MCP-1 were observed
within the first 24 hr following diagnosis; however, concen-
trations of these mediators rapidly declined to baseline by6 Correspondence: jonessa@cf.ac.uk
7 These authors contributed equally to this work. days 2–3 (Figure 1A).
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Figure 1. Leukocyte Numbers and Inflamma-
tory Mediator Concentrations in Peritoneal
Effluent Obtained from CAPD Patients with
Episodes of Bacterial Peritonitis
(A) Concentrations of total sIL-6R (filled cir-
cles), DS-sIL-6R (open circles), IL-6 (open di-
amonds), IL-8 (open squares), and MCP-1
(filled squares) in peritoneal effluent from
end-stage renal failure patients undergoing
CAPD were determined by ELISA. Values rep-
resent the mean  SEM from a total of ten
patients. Samples were collected over the
first 5 days post diagnosis of peritoneal in-
flammation (D1–D5) and 3–6 months (3m and
6m) later, when the infectious episode had
cleared. Effluent was also collected from
CAPD patients (n  4) who had not encoun-
tered a peritonitis episode, and values were
comparable with those presented for 3 and
6 months (data not shown).
(B) Peritoneal effluent from five individual
peritonitis patients was collected over a 5 day
period (D1–D5). Total cell counts were deter-
mined using a Coulter counter, and differen-
tial cell counts were performed on cytospin
preparations (filled circles, neutrophils; open
circles, mononuclear leukocytes). Values are
expressed as a percentage of the total leukocyte numbers and represent the mean  SEM.
(C) Leukocytes within the peritoneal effluent were monitored on day 1 as a clinical marker of infection. Patients with 100 leukocytes/mm3
were regarded as suffering from a peritoneal inflammation. Leukocyte numbers were correlated with levels of total sIL-6R seen on day 1 of
infection. The MINITAB statistical analysis package was used to analyze the regression fit (*, p  0.05).
Changes in the concentration of sIL-6R were monitored sIL-6R Mediates MCP-1 Expression by Human Peritoneal
Mesothelial Cellsduring the course of peritoneal infection. However, in as-
sessing sIL-6R levels, it is important to consider that both Regulation of leukocyte infiltration into the peritoneal cavity
is principally controlled via the secretion of chemokinesproteolytic (shedding) cleavage and differential mRNA splic-
ing (termed “PC-” and “DS-sIL-6R,” respectively) contribute and expression of adhesion molecules by the mesothelium
(Topley et al., 1993, 1996). In view of the intraperitonealto the total concentration of sIL-6R observed (Lust et al.,
1992; Horiuchi et al., 1994, 1998; Mu¨llberg et al., 1993, 1995). relationship between leukocyte numbers and sIL-6R levels
(Figure 1C), it is conceivable that sIL-6R release may con-Maximal concentrations of total sIL-6R were identified on
day 2 (day 1 versus day 2, p  0.0153; day 2 versus 3 tribute to leukocyte recruitment when combined with IL-6.
To assess the potential role of sIL-6R in modulating thismonths, p 0.00157); however, these did not coincide with
increases in DS-sIL-6R, which were highest on day 3 (day interaction, human peritoneal mesothelial cells (HPMC)
were tested for their ability to respond to the sIL-6R. Flow1 versus day 3, p  0.0284; day 3 versus 3 months, p 
0.0176). Thus, the initial increases in sIL-6R levels observed cytometry indicated that mesothelial cells might only re-
spond to IL-6 in the presence of sIL-6R, since expressionon day 1 appeared to be derived from increased IL-6R
shedding rather than secretion of DS-sIL-6R (Figure 1A). of membrane-bound IL-6R was not detected on the surface
of HPMC (data not shown).To examine the pattern of leukocyte recruitment encoun-
tered during peritonitis, differential cell counts were per- Initial studies examined the expression of chemokines by
HPMC following stimulation with IL-6 and sIL-6R. Althoughformed on leukocytes isolated from peritoneal effluent over
the 5 days of fluid collection. As illustrated in Figure 1B, the no change in chemokine secretion was observed when
HPMC were treated with IL-6 alone, release of the CC che-profile of intraperitoneal leukocyte accumulation revealed a
switch from a chiefly neutrophil influx to a predominantly mokine MCP-1 (CCL2) was significantly increased when
cells were stimulated with IL-6 in combination with sIL-6Rmononuclear cell (MNC) population by day 4. Furthermore,
peritoneal concentrations of total sIL-6R observed on day (Figure 2). Addition of sIL-6R alone also promoted small
but significant increases in MCP-1 production, suggesting1 of infection correlated with the number of infiltrating leuko-
cytes (Figure 1C). Since composition of the intraperitoneal that the known basal release of IL-6 by HPMC (Witowski
et al., 1996) is sufficient to facilitate formation of an activeleukocyte infiltrate encountered within the first 1–2 days of
infection predominantly consists of neutrophils (Figure 1B; sIL-6R/IL-6 complex (Figures 2A and 2C). Both anti-IL-6
(mAb-206) and anti-IL-6R (mAb-227) antibodies specificallyTopley et al., 1996), these infiltrating cells may account
for the increased sIL-6R levels. In support of this, human blocked release of MCP-1 in response to the sIL-6R/IL-6
complex (Table 1). Production of MCP-1 was also inducedneutrophils were found to release sIL-6R following a 30 min
stimulation with neutrophil-activating (ELR) CXC chemo- by HYPER-IL-6 (Figures 2B and 2C), a genetically engi-
neered sIL-6R-IL-6 fusion protein that is constructed sokines. Based on four independent experiments, activation
of neutrophils with either 100 nM GRO (CXCL1) or IL-8 that human IL-6 is covalently linked to human sIL-6R as a
unimolecular protein (Fischer et al., 1997; Peters et al.,(CXCL8) significantly (p  0.05) increased sIL-6R levels
above that of basal release (control 62.6  17 pg/ml; 100 1998). Thus, secretion of MCP-1 in response to sIL-6R sug-
gests that the sIL-6R/IL-6 complex might contribute to thenM IL-8 135.8 17 pg/ml; 100 nM GRO 141.7 20.1 pg/ml).
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Figure 2. Chemokine Production by Human
Peritoneal Mesothelial Cells
(A) Growth-arrested HPMC were stimulated
(24 hr) with either sIL-6R alone (0–100 ng/ml;
open circles) or in the presence of 10 ng/ml
IL-6 (filled circles).
(B) HPMC stimulated (24 hr) with defined
doses of HYPER-IL-6 (0–100 ng/ml).
(C) Time-dependent expression of MCP-1 by
HPMC stimulated with 10 ng/ml IL-6 (open
triangles), 50 ng/ml sIL-6R (open circles), sIL-
6R and IL-6 in combination (filled circles), 50
ng/ml HYPER-IL-6 (open squares), or vehicle
(filled squares). MCP-1 and IL-8 were quan-
tified using ELISA. Values represent the
mean  SEM from five independent experi-
ments (*, p 0.05; **, p 0.01; ***, p 0.001).
recruitment of monocytes and T lymphocytes to the perito- murine model of inflammation was developed. One of the
principle causative pathogens of this condition is Staphylo-neal cavity (Baggiolini, 1998). In contrast, sIL-6R-mediated
signaling alone did not promote expression of the CXC coccus epidermidis, and an appropriate and reproducible
model of peritoneal inflammation has been generated,chemokines GRO (CXCL1), IL-8 (CXCL8), or IP-10
(CXCL10) or of the CC chemokines MIP-1 (CCL3), RANTES based on a lyophilized cell-free supernatant (termed “SES”)
prepared from this bacterium. Consistent with episodes of(CCL5), or eotaxin (CCL11) (Figure 2 and Table 2).
human peritonitis (Figure 1B), intraperitoneal administration
of wild-type C57BL/6J mice (IL-6/) with SES resulted inModulation of Leukocyte Migration
a two-stage pattern of leukocyte recruitment. As illustratedby the sIL-6R/IL-6 Complex
in Figure 4A, this was characterized by an initial but transientExamination of inflammatory processes in IL-6/ mice has
accumulation of neutrophils, followed by a more sustainedpreviously shown that the absence of IL-6 results in height-
infiltration of mononuclear leukocytes. Correspondingened neutrophil recruitment (Xing et al., 1998). To test
quantification of murine chemokine expression profiles re-whether sIL-6R-mediated signaling plays a role in control-
vealed that induction of MIP-2 and KC (murine functionalling the number of neutrophils attracted to an inflammatory
counterparts of IL-8 and GRO) was extremely transient,insult, IL-8 and GRO secretion by HPMC in response to
with optimal levels occurring within 30–60 min after adminis-IL-1 (10 pg/ml) or TNF (100 pg/ml) was monitored in the
tration of SES (Figure 4B). In contrast, intraperitoneal MCP-1presence of IL-6 and its soluble receptor. As illustrated in
levels were more sustained, with a maximal concentrationFigure 3, IL-1- and TNF-mediated release of IL-8 and
plateau resulting 1–3 hr after initiation of the inflammatoryGROwas significantly attenuated by the inclusion of either
event (Figure 4B).IL-6 in combination with sIL-6R or by HYPER-IL-6. Addition
To establish the role of the sIL-6R/IL-6 complex in perito-of IL-6 or sIL-6R alone had no affect on HPMC ELR CXC
neal inflammation, IL-6-deficient (IL-6/) mice were chal-chemokine expression (Figure 3A). Stimulation of HPMC
lenged with SES and IL-6 signaling reconstituted throughwith the sIL-6R/IL-6 complex did not modify the secretion
intraperitoneal administration of HYPER-IL-6. Since theof MCP-1 induced by IL-1, with costimulation resulting
construction of HYPER-IL-6 prevents the inherent dissocia-in an additive response (Table 2). Inhibition of chemokine
tion-association of the ligand-receptor complex (i.e., IL-6expression appeared to be specific for ELR CXC chemo-
sIL-6R ⇔ IL-6/sIL-6R complex), IL-6 signaling only occurskines, since the sIL-6R/IL-6 complex did not prevent pro-
via sIL-6R (Fischer et al., 1997). Consequently, this elimi-duction of RANTES (CCL5) or IP-10 (CXCL10) by IL-1-
nates the ability of human IL-6 itself to transmit signals viastimulated HPMC (Table 2). In contrast, neither IL-1 nor
the murine IL-6R (Peters et al., 1996). Optimal time pointsthe sIL-6R/IL-6 complex induced release of MIP-1 (CCL3)
or eotaxin (CCL11) from HPMC. for analyzing the role of sIL-6R in vivo were based upon the
profiles of leukocyte recruitment and chemokine expression
presented in Figure 4. As illustrated in Figure 5A, intraperito-Effect of HYPER-IL-6 on Leukocyte Recruitment
neal administration of HYPER-IL-6 significantly impaired thein a Murine Model of Peritoneal Inflammation
extent of neutrophil recruitment observed in IL-6/ miceTo mimic the progression of a bacterial-peritonitis episode
typically seen in CAPD patients (Brauner et al., 1996), a challenged with SES. This reduction in neutrophil accumula-
Table 1. Blockade of MCP-1 Production by Specific Monoclonal Antibodies
Experimental Conditions mAb-206 mAb-227 mAb-C20
Control 2685  607 2967  83 2785  360
Control  mAb 2464  646 2843  177 2784  575
50 ng/ml sIL-6R  10 ng/ml sIL-6 5778  727 6759  200 5960  62
50 ng/ml sIL-6R  10 ng/ml sIL-6  mAb 2977  1033* 3067  143*** 5855  658
Inhibition of MCP-1 (CCL2) release by HPMC by blocking anti-IL-6 (10 	g/ml mAb-206) and anti-IL-6R (10 	g/ml mAb-227) antibodies. An
anti-STAT3 antibody was used as control (mAb-C20; Santa Cruz). Values represent the mean (pg/ml)SEM from three independent experiments
using different primary cell isolates (*, p  0.05; ***, p  0.001).
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Table 2. The Impact of IL-6 and Its Soluble Receptor on IL-1 Induction of Certain Chemokines
CC Chemokines CXC Chemokine
Experimental Conditions MCP-1 RANTES MIP-1 Eotaxin IP-10
Control 2423  508 24.1  11 LD LD LD
IL-6 2431  388 28.2  23 LD LD LD
sIL-6R 3749  838 41.5  35 LD LD LD
sIL-6R  IL-6 6858  1155* 30.2  23 LD LD LD
IL-1 7267  1026* 533  86* LD LD 120  21*
IL-1  IL-6 7746  2090 524  161 LD LD 140  10
IL-1  sIL-6R 10454  2416 449  87 LD LD 182  28
IL-1  IL-6  sIL-6R 13734  3340 433  78 LD LD 140  27
Mesothelial cells were stimulated for 24 hr with the indicated combinations of 10 ng/ml IL-6, 50 ng/ml sIL-6R, and 10 pg/ml IL-1. Chemokine
levels were determined using specific ELISA and represent the mean (pg/ml)SEM from three to four independent experiments. Concentrations
that fell below detection limit (LD) of each assay are indicated. Predicted additive values for MCP-1 release in response to IL-1  IL-6, IL-
1  sIL-6R, and IL-1  IL-6  sIL-6R were 7275, 9064, and 12,173 pg/ml, respectively. Statistically, significant increases above control
values for cells stimulated with either IL-1 alone or the sIL-6R/IL-6 complex are shown (*, p  0.05).
tion was also paralleled by a suppression of intraperitoneal through membrane-bound IL-6R (Jostock et al., 2001;
Atreya et al., 2000; Mu¨ller-Newen et al., 1998). AdditionMIP-2 and KC expression (Figures 5B and 5C). Conse-
quently, sIL-6R-mediated signaling appears to curb neutro- of sgp130 significantly enhanced SES-induced neutrophil
accumulation and expression of the ELR CXC chemokinesphil recruitment and presumably activation of other chemo-
kine-mediated neutrophil responses, such as degranulation KC and MIP-2 (Figure 6). This is consistent with the neutro-
philic phenotype of the inflammatory response observedand superoxide generation (Baggiolini, 1998). To confirm
that these effects were the direct result of sIL-6R activity, in SES-treated IL-6/ mice. Consequently, suppression of
ELR CXC chemokine expression via sIL-6R-mediated sig-IL-6/ mice were administered with SES in combination
with recombinant soluble gp130 (sgp130). This naturally naling directly impacts on the degree of neutrophil recruit-
ment encountered.occurring protein inhibits cellular responses elicited by the
sIL-6R/IL-6 complex and does not affect IL-6 signaling To test whether sIL-6R-mediated signaling also plays a
Figure 3. Modulation of IL-1- and TNF-
Mediated Chemokine Expression by sIL-6R
Production of chemokines by IL-1 (10 pg/
ml) and TNF (100 pg/ml) stimulated HPMC
(24 hr) was quantified using ELISA. (A) HPMC
were stimulated with IL-1 or TNF in combi-
nation with IL-6 (10 ng/ml) and sIL-6R (50 ng/
ml) as indicated. Chemokine release in re-
sponse to the sIL-6R/IL-6 complex alone is
also represented. (B) HPMC stimulated with
HYPER-IL-6 (0–100 ng/ml) alone (open cir-
cles) or in combination with IL-1 or TNF
(filled circles). The mean  SEM from five
independent experiments is presented (*, p
0.05; **, p  0.01).
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Figure 4. Characterization of Murine Perito-
neal Inflammation Model
Wild-type C57BL/6J (IL-6/) mice were intra-
peritoneally administered with SES (filled cir-
cles) or PBS (open circles), and at designated
intervals the peritoneal cavity was lavaged.
(A) Differential cell counts were performed on
cytospin preparations to determine neutro-
phil and MNC numbers. (B) Profiles of chemo-
kine expression were quantified using spe-
cific ELISA for MCP-1, KC, and MIP-2.
Negligible chemokine levels were detected at
24 and 48 hr after SES stimulation. Values
represent the mean  SEM (n  6 mice/con-
dition).
direct role in regulating mononuclear cell infiltration, a time were attained 3 hr after inflammatory stimulation. However,
in contrast to the extended profile of MCP-1 expressioncourse of MCP-1 expression was monitored in IL-6/ mice
challenged with either SES or in combination with HYPER- observed in IL-6/ mice (Figure 4B), induction was ex-
tremely transient, and MCP-1 levels returned to baselineIL-6 (Figure 7A). When IL-6/ mice were exposed to SES
alone, optimal intraperitoneal concentrations of MCP-1 within 6 hr after the initial insult (Figure 7A). This implies
Figure 5. Modulation of Neutrophil Infiltration and Chemokine Expression by HYPER-IL-6 In Vivo
SES-peritoneal inflammation was established in IL-6/ mice. Mice were intraperitoneally challenged with sterile PBS (control), 40 ng/mouse
HYPER-IL-6, SES alone, or SES in combination with HYPER-IL-6. (A) Neutrophil recruitment was determined by differential cell counts of
lavage fluid obtained from each experimental condition after 3 and 4.5 hr exposure. In each case, values represent the mean  SEM (n  5
to 6 mice/condition; *, p  0.05 SES versus SES  HYPER-IL-6). (B) Mice were exposed to PBS (open squares), HYPER-IL-6 (filled squares),
SES (open circles), or SES in combination with HYPER-IL-6 (filled circles). At set intervals, the peritoneal cavity was lavaged, and levels of
KC and MIP-2 were quantified using ELISA (n  6 to 8 mice/condition; *, p  0.05 SES versus SES  HYPER-IL-6). (C) Mice were challenged
for 30 min, after which time the peritoneal membrane was dissected out and total RNA extracted for RPA analysis of KC expression (similar
results were obtained for MIP-2; data not shown). Profiles for each experimental condition are shown (two to three mice per experimental
condition are represented from a total of six animals per condition).
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Figure 6. Modulation of Neutrophil Infiltra-
tion and Chemokine Expression by sgp130 In
Vivo
Wild-type (IL-6/) mice were intraperitone-
ally administered with SES alone or together
with 250 ng/mouse recombinant soluble
gp130 (R&D Systems) as illustrated. (A) Fol-
lowing a 1 hr (for chemokine determination)
and (B) 3 hr (to monitor neutrophil influx) chal-
lenge, the peritoneal cavity was lavaged, and
inflammatory parameters were analyzed (n 
6 mice/condition; *, p  0.05; **, p  0.01).
that IL-6, at least in part, contributes to the regulation of mononuclear leukocytes (Figure 7B). Taken together, these
in vivo data support a role for sIL-6R in differentially regulat-MCP-1 in vivo. Indeed, combined intraperitoneal challenge
of IL-6/ mice with SES and HYPER-IL-6 restored the time ing recruitment of neutrophils and mononuclear leukocytes
during inflammation.course of MCP-1 expression to that seen in IL-6/ mice
and resulted in a more rapid induction and prolongation of
the MCP-1 expression profile (compare Figures 4B and 7A).
DiscussionA similarly limited induction of MCP-1 has also been re-
ported in IL-6/ mice following exposure to an air pouch
model of inflammation (Romano et al., 1997); however, res- This study has examined regulation of leukocyte infiltration
into the peritoneal cavity by IL-6 and its soluble receptor.toration of MCP-1 levels by the designer cytokine HYPER-
IL-6 suggests that this is facilitated by sIL-6R. The observa- As with many other local inflammatory situations, leukocyte
recruitment during peritonitis is characterized by an earlytion that IL-6/ mice exposed to either SES alone or SES
together with HYPER-IL-6 attain similar intraperitoneal intraperitoneal accumulation of neutrophils, which, as they
are cleared, are replaced by a more sustained populationMCP-1 levels by 3 hr after the induction of inflammatory
response is also intriguing and suggests that other media- of mononuclear cells. Ultimately, it is this switch in the
leukocyte recruitment pattern which appears to dictate thetors are involved in this process. Likewise, the inability of
HYPER-IL-6 itself to promote dramatic increases in MCP-1 process of successful clearance of the infectious agent and
restoration of tissue homeostasis (Bellingan et al., 1996;above basal levels implies that IL-6 and its soluble receptor
might act in combination or synergistically with other inflam- DiTirro et al., 1998). To date, factors controlling this critical
step have remained largely undefined. Through combinedmatory agents. In either likelihood, augmentation of MCP-1
levels by HYPER-IL-6 suggests that sIL-6R-mediated sig- analysis of clinical samples from patients with peritonitis
and a series of in vitro and in vivo approaches, evidencenaling contributes to the intraperitoneal accumulation of
Figure 7. Modulation of MCP-1 Levels and
Mononuclear Cell Infiltration by HYPER-IL-6
In Vivo
(A) IL-6/ Mice were intraperitoneally chal-
lenged with sterile PBS (open squares), 40
ng/mouse HYPER-IL-6 (filled squares), SES
alone (open circles), or SES in combination
with HYPER-IL-6 (filled circles). At set inter-
vals, mice were sacrificed, and MCP-1 levels
were measured in lavage fluid. (B) IL-6/ mice
were treated as indicated, and intraperitoneal
accumulation of mononuclear leukocytes
was determined after 8 and 12 hr. In all cases,
values represent the mean  SEM (n  5 to
7 mice/condition; *, p  0.05; **, p  0.01
SES  HYPER-IL-6 versus SES alone).
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is presented which proposes a central role for IL-6 and its was established. S. epidermidis is a major causative patho-
soluble receptor in the regulation of this temporal switch gen of dialysis-associated peritonitis, and, by administrat-
in leukocyte recruitment. In particular, the presence of sIL- ing a defined dose of a cell-free supernatant (SES) derived
6R in combination with IL-6 affects recruitment of leukocyte from this pathogen, we have been able to establish a murine
subpopulations through the concurrent ability of the active model which closely resembles the human condition. In
complex to suppress ELR CXC chemokine expression in- peritoneal infections, inflammation is driven by the early
duced by proinflammatory cytokines (IL-1 and TNF) while activation of proinflammatory cytokines (IL-1 and TNF),
directly promoting secretion of the CC chemokine MCP-1. which precede the elaboration of other immunomodulatory
The mesothelium which lines the whole of the peritoneal and chemotactic factors as well as leukocyte recruitment
and pleural cavities is the principal IL-6-producing cell (Brauner et al., 1996; Topley et al., 1996). Consistent with
within the peritoneal cavity and synthesizes large amounts human peritonitis, the SES model exhibits a similar pattern
of this cytokine upon inflammatory challenge (Witowski et of inflammatory events, albeit that the time frame of induc-
al., 1996). Mesothelial cells, however, were found not to tion is condensed within the animals. Indeed, the observed
express the cognate IL-6R, which infers that these cells changes in chemokine expression in our model are pre-
would remain unresponsive to IL-6 itself. It is therefore ap- ceded by increases in both IL-1 and TNF (R.M.M. and N.T.,
parent that stimulation of the mesothelium by IL-6 can only unpublished data). Based on the clinical data presented in
occur through the action of an sIL-6R. As a result, the ex- Figure 1, levels of human sIL-6R peak at day 2 following
tremely high IL-6 concentrations encountered during the onset of an infectious episode. Consequently, elevated sIL-
early onset of infection (Figure 1A) might be considered to 6R levels occur later than that of IL-1 and TNF. Although
serve a largely redundant role until such times that sIL- the lack of a suitable antibody pair prevented the monitoring
6R levels are sufficiently raised. In this respect, the high of murine sIL-6R expression in vivo, the inhibitory effects
intraperitoneal IL-6 levels would ensure optimal formation
of sgp130 presented in Figure 6 confirm that IL-6 controls
of the agonistic sIL-6R/IL-6 complex, which indicates that
leukocyte recruitment through sIL-6R and not via the cog-
the events controlling cellular sIL-6R release is an integral
nate IL-6R (Jostock et al., 2001; Atreya et al., 2000; Mu¨ller-part of this process. The absence of a cognate IL-6R on
Newen et al., 1998). Indeed, the phenotype observed duringmesothelial cells not only indicates that these cells are un-
induction of an inflammatory response in IL-6/ mice ad-able to respond to IL-6 but that they are unable to contribute
ministered with sgp130 closely resembles that previouslyto the intraperitoneal concentrations of sIL-6R encountered.
reported in IL-6/ mice (Xing et al., 1998). A fact that isConversely, the correlation between leukocyte infiltration
underlined by the reconstitution of sIL-6R-mediated signal-and sIL-6R levels presented in Figure 1C suggests that
ing in IL-6/ mice with HYPER-IL-6, which imposes an in-infiltrating neutrophils are a potential source of sIL-6R. In
flammatory constraint on the extent of neutrophil re-this respect, previous studies have shown that sIL-6R is
cruitment.shed from leukocytes following stimulation with f-Met-Leu-
Additional information based on the analysis of clinicalPhe and C-reactive protein (Modur et al., 1997; Jones et
samples also shows that sIL-6R levels are independentlyal., 1999), while evidence presented in this current report
controlled during disease progression by both differentialshows that IL-8 and GRO are capable of activating sIL-
mRNA splicing and proteolytic (shedding) cleavage. Conse-6R release. It is therefore conceivable that the initial at-
quently, two distinct sIL-6R isoforms (termed “DS-sIL-6R”traction of neutrophils by ELR CXC chemokines indirectly
and “PC-sIL-6R”) may contribute to the overall propertiescontrols the degree of neutrophil infiltration to an appro-
priate level by regulating IL-6R shedding. These events of this soluble cytokine receptor. It is apparent from these
would facilitate formation of an sIL-6R/IL-6 complex, which studies that increased IL-6R shedding may account for the
suppresses the proinflammatory cytokine-driven expres- sIL-6R levels encountered during early stages of the inflam-
sion of ELRCXC chemokines. Thus, the processes orches- matory response. In this respect, neutrophils have been
trating the initial attraction of neutrophils (i.e., ELR CXC shown not to secrete detectable levels of DS-sIL-6R (Jones
chemokine secretion) might be directly coupled to those et al., 1999). In contrast, the elevated concentrations of DS-
regulating their eventual clearance. This scenario is analo- sIL-6R seen on day 3 of infection infers a role for this isoform
gous to the role of soluble L-selectin (CD62L), which is shed during the subsequent stages of the disease process; how-
from infiltrating leukocytes as a mechanism to antagonize ever, to date, no functional distinction has been made be-
ensuing leukocyte recruitment (Walcheck et al., 1996). In tween these two soluble forms.
addition, the initial recruitment and activation of neutrophils Previous investigations have assigned both pro- and anti-
might ultimately act as a trigger for moderating the subse- inflammatory properties to the action of IL-6 (Romano et
quent recruitment of mononuclear leukocytes. Based on al., 1997; Xing et al., 1998). The present study provides
this model of neutrophil activation and the ability of sIL-6R direct evidence that the biological activities of sIL-6R serve
to directly promote MCP-1 expression, it is proposed that as a potential explanation for the apparent paradox of IL-6
IL-6R shedding from infiltrating neutrophils may, in part, being able to act as both a pro- and antiinflammatory media-
account for the switch between the initial neutrophilic stage
tor. The ability of sIL-6R to modulate a switch in the accu-
of infection and the more sustained influx of mononuclear
mulation of leukocyte subpopulations suggests that the
leukocytes. It is this transition from the recruitment of leuko-
sIL-6R/IL-6 complex might act as an important resolutioncytes typically associated with innate immunity to those
factor in the successful clearance of bacterial infections.important in acquired immunity that appears to facilitate
the successful resolution of inflammation and the return to
normal tissue homeostasis without organ damage (DiTirro Experimental Procedures
et al., 1998).
To investigate the precise mechanism by which sIL-6R/ Patients
IL-6 signaling controls leukocyte recruitment and to sub- Dialysis fluid was collected in accordance with ethical approval from
stantiate the findings obtained through our clinical and in the Bro Taf Health Authority from end-stage renal failure patients
currently being treated at the University Hospital of Wales. All pa-vitro analysis, a murine model of peritoneal inflammation
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tients were receiving a standard peritoneal dialysis therapy of four presented in parentheses, in accordance with the recently proposed
chemokine classification system (Zlotnik and Yoshie, 2000).exchanges per day, with 2 liters of dialysis fluid. Peritoneal effluent
from patients undergoing stable peritoneal dialysis (noninfected
controls) and those with infections of defined severity were collected Animals
on ice at intervals during infection (days 1–5) and stable peritonitis. Experiments were performed in 6- to 12-week-old C57BL/6J wild-
Mediator concentrations were compared in effluent obtained from type and interleukin-6-deficient (IL-6/) mice. Details relating to
the overnight dwell (12 hr) exchange period. Samples were rendered generation of the IL-6/ mice is described elsewhere (Kopf et al.,
cell free by centrifugation (150 
 g), filtered, and stored at 70C. 1994). Procedures were carried out following Home Office approval,
Patients with bacterial episodes of peritonitis were uniformly treated under project license number PPL-40/2131.
with a standard regime of ciprofloxacin and vancomycin as outlined
by the International Society for Peritoneal Dialysis (ISPD) guidelines
Induction of SES Peritonealfor the treatment of adult peritoneal dialysis-related peritonitis
A lyophilized cell-free supernatant (SES) was prepared from S. epi-(Keane et al., 2000).
dermidis WE that had previously been isolated from a CAPD patient
with peritonitis (Mackenzie et al., 1990). In brief, bacteria were iso-
Isolation of Human Neutrophils lated from a stationary phase culture by centrifugation (3000 rpm
Neutrophils were isolated from 20 ml of whole blood obtained by at 4C for 20 min) and resuspended in Tyrodes salt solution without
antecubital venipuncture of nonsmoking normal healthy volunteers, Gelatin (GIBCO) to an absorbance of 1.0 at 560 nm and incubated
as previously described (Jones et al., 1999). Neutrophil preparations at 37C for 24 hr. Suspensions were centrifuged (3000 rpm at 4C
were found to be 95% pure as assessed by differential Wright for 20 min) and the supernatant filtered prior to dialysis against
staining. All stimulations were preformed at 37C in serum-free distilled water. Fractions were freeze dried and aliquots stored at
RPMI-1640 containing 2 mM L-glutamine, 100 U/ml penicillin, and 70C until required. SES preparations were free of live bacteria,
100 	g/ml streptomycin (Life Technologies). as assessed by the lack of bacterial growth on DST agar (Oxoid).
Preparations were reconstituted in PBS prior to in vivo use and the
potency of SES standardized by quantifying secretion of murineIsolation and Culture of Human Peritoneal Mesothelial Cells
IL-6 from the macrophage cell line RAW-264 exposed to definedHPMC were isolated by serial tryptic (0.1% w/v trypsin and 0.02%
doses of SES. Induction of peritoneal inflammation in wild-type andw/v EDTA) digestion of omental tissue from consenting patients
IL-6/ mice was established by intraperitoneal injection of a definedundergoing elective abdominal surgery (Topley et al., 1993). Cells
500 	l dose of SES. Control populations were administered withwere cultured in Earle’s buffered-199 medium containing 10% (v/v)
sterile PBS. At designated time intervals, mice were sacrificed andfetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 	g/ml
the peritoneal cavity lavaged with 2 ml ice-cold PBS containing 5streptomycin, 5 	g/ml transferrin, 5 	g/ml insulin, and 0.4 	g/ml
U/ml heparin. Leukocyte numbers were assessed by differential cellhydrocortisone (Life Technologies or Sigma) at 37C in a humidified
counts and inflammatory mediator concentrations quantified using5% CO2 atmosphere. Prior to experimentation, HPMC monolayers
ELISA. Sections of the perital peritoneum were dissected away andwere growth arrested for 48 hr in the absence of serum. Under these
snap frozen in liquid nitrogen for RNA isolation. To determine theconditions, HPMC remain in a viable and quiescent state for up to
role of the sIL-6R in vivo, IL-6 signaling in IL-6/ mice was reconsti-96 hr (Topley et al., 1993). All stimulations were performed in the
tuted with HYPER-IL-6 (40 ng/mouse), which, due to the speciesabsence of serum and on isolates no older than the second passage.
specificity of human IL-6 and its soluble receptor, enables activation
of both human and murine gp130 (Peters et al., 1996; Rakemann etFACS Analysis
al., 1999). Similarly, to block sIL-6R-mediated responses in IL-6/Cell surface expression of IL-6R was assessed by cytofluorometry
mice, animals were intraperitoneally administered with human solu-(FACScalibre; Becton Dickinson) using a monoclonal anti-human
ble gp130 (250 ng/mouse; from R&D Systems), which has beenIL-6R antibody (mAb-227; R&D Systems) as previously described
shown to inhibit murine IL-6 signaling (Atreya et al., 2000).(Jones et al., 1999). Antibody recognition was detected with a PE-
conjugated secondary antibody and compared with autofluores-
RNA Isolation and RNase Protection Assaycence control samples exposed to secondary antibody alone. Data
Total RNA was extracted from tissue samples using RNA isolatorwas acquired from 5000 gated events per sample.
(Genosys) and analyzed using an RPA murine chemokine expression
kit (Pharmingen, Becton Dickinson). Chemokine-specific antisense
Generation of HYPER-IL-6
cRNA riboprobes were radiolabeled with [32P]UTP using T7 poly-
Construction, expression, and characterization of the HYPER-IL-6
merase and hybridized at 56C for 12–16 hr with 10 	g of total RNA
chimera was performed as previously described (Fischer et al., 1997;
or tRNA, which was used as a negative control. Unprotected sec-
Peters et al., 1998).
tions of RNA were digested at 30C for 45 min with ribonuclease-A
and double-stranded ribonuclease-resistant RNA products ana-
Determination of Inflammatory Mediator Concentrations lyzed by electrophoresis in a 6% polyacrylamide/8M urea gel fol-
Inflammatory mediator concentrations were quantified using sand- lowed by autoradiography.
wich ELISA techniques. Human sIL-6R levels were analyzed using
matched antibody pairs (mAb-227 and BAF-227) from R&D Systems Statistical Analysis
(Jones et al., 1999). Levels of DS-sIL-6R were measured using a Data were analyzed using an unpaired Student’s t test. Analysis of
monoclonal antibody specific for the unique COOH terminal se- the regression fit presented in Figure 1C was determined using the
quence (GSRRRGSCGL) of DS-sIL-6R (mAb 2F3) as a capture anti- MINITAB statistical analysis package.
body and was used in combination with a biotinylated anti-IL-6R
polyclonal antibody (BAF-227) (Horiuchi et al., 1998; Jones et al.,
Acknowledgments1998, 1999). Quantification was achieved using a baculovirus ex-
pressed form of DS-sIL-6R (Horiuchi et al., 1998). Human MCP-1
The authors wish to thank Drs. Anwen Williams, Brad Spiller, Jeffrey(CCL2) and IL-6 levels were determined using a matched antibody
Horton, and Mrs. Janine Beavis for their technical advice and sup-pair OptEIA ELISA set from PharMingen, Becton Dickinson. Human
port. Research funding was provided through a Wellcome TrustRANTES (CCL5) and IL-8 (CXCL8) concentrations were quantified
Project Grant (N.T. and S.A.J.). S.H., N.Y., and S.A.J. are recipientswith appropriate matched antibody pairs from R&D Systems (mAb-
of a Wellcome Trust Biomedical Collaboration Grant. T.S.W. and678/BAF-278 and mAb-208/BAF-208, respectively). Levels of human
R.M.M are supported through Ph.D. studentships awarded to N.T.GRO (CXCL1), IP-10 (CXCL10), MIP-1 (CCL3), murine MCP-1,
by the University of Wales College of Medicine and the MedicalMIP-2, and KC were analyzed using R&D Systems ELISA kits. Human
Research Council (UK), respectively.eotaxin (CCL11) was measured using an Amersham BIOTRAK ELISA
kit (kindly provided by Dr. Jeffrey Horton, Amersham Pharmacia).
The new nomenclature assigned to each of the chemokines listed is Received November 3, 2000; revised April 26, 2001.
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